Studies of high, moderate, or low quality were categorised as being above quality threshold, with studies of very low quality considered below quality threshold.
Scores of 1 2 were considered as low quality, while scores of 3 5 were considered as high quality.
Out of seven, no or less than 3 checkups is considered as "low quality" ANC, 3 to 4 checkups is considered as medium quality ANC, 4 and above checkups is considered as a high-quality ANC check-up.
Studies with five, six or seven plusses were considered as medium quality studies, and studies with four or less plusses were considered as low quality studies.
7 Scores less than 3 were considered as low quality.
ST have been considered as low quality sequences, i.e. enriched in sequencing errors and may be excluded from analysis by standard bioinformatics procedures.
It consisted in the elimination of BAC fingerprints comprising less than 30% of the average number of tags per BAC (≤ 4 tags; considered as low quality fingerprints) and those with more than 2.5 times the average number of tags per BAC (≥ 40 tags; which is expected to include the vast majority of those that result from chimerical BACs or cross contamination of BACs in the same well, if present).
Therefore, our rating differed from the original AMSTAR and with a maximum obtainable score of 9 we considered 0 4 as low quality, and 5 or more as moderate to high quality.
For example, blinding may not be feasible in many non-drug trials, and it would not be reasonable to consider the trial as low quality because of the absence of blinding.
We considered scores of ≤2 as low quality and a score of ≥3 as high quality because none of the studies were double-blinded, due to the visibly different properties of the comparators.
A score of ≥ 11 points was considered high quality and a score < 11 points as low quality.
